Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

Noventra Pharma Thymalin 75 mg

R 0.00
Add to WishlistCompare

Noventra Pharma Thymalin 75 mg — Multidose Pen

Immune-System Research | Thymic Peptides | Cellular Ageing

Product Overview

Noventra Pharma Thymalin 75 mg is a multidose pen-format product labelled with a total strength of 75 mg.

Thymalin is a thymus-derived peptide preparation investigated for its potential role in immune regulation, immune-cell activity and age-associated biological changes. The thymus plays an important role in the development and maturation of T lymphocytes, which are essential components of the body's adaptive immune system.

Research into thymalin has explored how thymic peptide preparations may influence immune-related markers and physiological processes in older populations.

Key Research Findings

1. Immune-cell activity

Clinical research has investigated thymalin in relation to immune-cell populations, including T lymphocytes and natural killer cells. A 2021 study involving older hospitalised patients with severe COVID-19 reported changes in several immune-cell measurements following thymalin treatment alongside standard care. The study's design limits the conclusions that can be drawn about causation or broader clinical effectiveness.

2. Immune regulation in older populations

Historical studies have explored thymalin in older adults experiencing age-associated changes in immune function. Some reported improvements in selected immune markers, but the findings require stronger independent replication using modern clinical-trial methods.

3. Research into biological ageing

Thymalin has attracted scientific interest in biogerontology, the study of biological ageing. Researchers have investigated whether thymic peptide preparations may influence age-associated physiological changes. However, evidence that thymalin extends human lifespan or reliably reverses biological ageing has not been established to modern clinical standards.

4. Thymic peptide biology

The thymus is central to T-cell development and immune-system maturation. Research into thymalin seeks to understand whether thymus-derived peptide preparations influence related biological processes. The precise composition of thymalin preparations can vary, making it important to distinguish findings for one preparation from claims about another product.

Key Features
  • 75 mg total Thymalin content, as labelled on the packaging.
  • 2 ml pre-filled multi-dose pen format.
  • 200-click pen with a visible dose-selection window. Click count describes the pen format, not a recommended dosing schedule.
  • Pack includes one pre-filled pen and eight sterile, single-use injection needles.
  • Labelled for single-patient use only.
  • Noventra Pharma branded presentation.
Dosage & Usage

Dose: 5 mg

Clicks: 13 clicks

Frequency: Daily for 10 consecutive days

Break between cycles: 6 months before repeating the next cycle

FAQ's & Tips

What is Noventra Pharma Thymalin 75 mg?

It is a Thymalin product supplied in a pre-filled 2 ml multi-dose pen. The packaging lists a total Thymalin content of 75 mg.

What is included in the pack?

The packaging lists one multi-dose pre-filled pen and eight sterile, single-use injection needles.

Does 75 mg refer to the total pen content?

Yes. The packaging identifies 75 mg as the total Thymalin content in the 2 ml pen, not the amount per click.

How many clicks does the pen have?

The packaging describes a 200-click multi-dose pen. Click count is a product-format detail, not a recommended dose or usage schedule.

Can the pen be shared?

No. The packaging states that the pen is for single-patient use only. Supplied needles are labelled sterile and single-use.

Does this product guarantee immune support or anti-ageing results?

No guaranteed health outcomes are stated here. Research interest in a compound does not establish the safety or effectiveness of this specific product.

Where can I find storage and handling instructions?

Refer to the instructions supplied with the product for storage conditions, handling requirements and expiry information. If anything is unclear or missing, contact the supplier before use.

Does this FAQ provide a dosing or administration protocol?

No. This FAQ describes the product presentation only and does not provide a dosing schedule, administration instructions or personalised medical advice. Consult a qualified healthcare professional for questions about suitability and safety.

Research

Thymalin Research & Scientific References

Published research has explored Thymalin in immune-cell differentiation, inflammatory signalling and experimental bone repair. The studies below concern experimental Thymalin preparations or its components, not the Noventra Pharma 75 mg multi-dose pen. They do not establish this product’s clinical safety, effectiveness or equivalence to the materials studied.

1. Human hematopoietic stem-cell differentiation (2020)

Khavinson and colleagues studied Thymalin’s effects on human hematopoietic stem cells and markers associated with T-cell maturation. The authors reported changes in CD44, CD117 and CD28 expression. These laboratory findings explore a possible biological mechanism; they do not demonstrate a clinical benefit from this pen.

Read: Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.

2. Inflammatory signalling and peptide components (2023)

Linkova and colleagues investigated Thymalin and its KE and EW dipeptide components using molecular modelling, bioinformatics and an inflammation model involving human peripheral blood mononuclear cells. The study reported reduced production of selected inflammatory cytokines in the cell model. It was not a clinical trial of this product and does not establish prevention or treatment of COVID-19.

Read: The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.

3. Experimental bone repair in rats (2024)

Boiko and colleagues examined mandibular bone-defect repair in 48 rats, comparing Thymalin, a hydroxyapatite-containing bone graft and their combination. The authors reported enhanced repair in the combined-treatment group. This animal study does not establish bone-healing benefits in humans or support a treatment recommendation for this pen.

Read: Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study.

Understanding the Evidence

Laboratory and animal findings cannot be assumed to translate into benefits in people. Formulation, composition and study conditions matter. These references are educational and are not dosing instructions, medical advice or proof of approval for this specific product.

Reviews